TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, Subbiah V, Fu S, Karp D, Falchook GS, Tsimberidou AM, Piha-Paul S, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ, Hong D, Kurzrock R.
Wheler JJ, et al. Among authors: kurzrock r.
Mol Cancer Ther. 2016 Oct;15(10):2475-2485. doi: 10.1158/1535-7163.MCT-16-0196. Epub 2016 Jul 27.
Mol Cancer Ther. 2016.
PMID: 27466356